BOSTON & PERTH, Australia--(BUSINESS WIRE)--Global bio-nanotech company pSivida Limited (NASDAQ:PSDV)(ASX:PSD)(Xetra:PSI) today announced that the first patient has been implanted with BrachySilTM for the treatment of inoperable pancreatic cancer at Guys and St Thomas’ NHS Foundation Trust Hospital in London, a major center for cancer therapy in the United Kingdom.
